BAIJIN LIFE SCI Shares Surge Over 60% Following Strategic Collaboration in Clinical Cell Therapy

Stock News

Jun 22

Shares of BAIJIN LIFE SCI (01466) have surged more than 60%. At the time of writing, the stock is up 50%, trading at HK$0.93 with a turnover of HK$12.29 million.

The significant movement follows a recent company announcement. The firm's indirectly wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with Fuyao Yuanqi Biotechnology Co., Ltd. (Fuyao Yuanqi). This agreement pertains to strategic collaboration within the clinical cell therapy field.

Fuyao Yuanqi's core technology originates from the commercialization of scientific research achievements from leading Chinese higher education and research institutions. The company has established specialized technology transfer cooperation arrangements and has secured exclusive licensing for related patents. Fuyao Yuanqi also possesses experience in filing for clinical cell drug research.

Previously, Beijing Baijin, the indirectly wholly-owned subsidiary of BAIJIN LIFE SCI, signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. (Youhuan Bio). Under this agreement, Beijing Baijin will invest in Youhuan Bio by subscribing to its equity. The aim is to establish a globally leading circular RNA (circRNA) technology research and development platform and, by leveraging this platform, to deepen technological innovation in the cell therapy sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1151123163"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151123163\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151123163?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 15:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151123163","market":"hk","top_or_hot":-1,"title":"BAIJIN LIFE SCI Shares Surge Over 60% Following Strategic Collaboration in Clinical Cell Therapy","media":"Stock News","content":"<p>Shares of <b>BAIJIN LIFE SCI</b> (<b>01466</b>) have surged more than 60%. At the time of writing, the stock is up 50%, trading at HK$0.93 with a turnover of HK$12.29 million.<br><br>The significant movement follows a recent company announcement. The firm's indirectly wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with Fuyao Yuanqi Biotechnology Co., Ltd. (Fuyao Yuanqi). This agreement pertains to strategic collaboration within the clinical cell therapy field.<br><br>Fuyao Yuanqi's core technology originates from the commercialization of scientific research achievements from leading Chinese higher education and research institutions. The company has established specialized technology transfer cooperation arrangements and has secured exclusive licensing for related patents. Fuyao Yuanqi also possesses experience in filing for clinical cell drug research.<br><br>Previously, Beijing Baijin, the indirectly wholly-owned subsidiary of <b>BAIJIN LIFE SCI</b>, signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. (Youhuan Bio). Under this agreement, Beijing Baijin will invest in Youhuan Bio by subscribing to its equity. The aim is to establish a globally leading circular RNA (circRNA) technology research and development platform and, by leveraging this platform, to deepen technological innovation in the cell therapy sector.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAIJIN LIFE SCI Shares Surge Over 60% Following Strategic Collaboration in Clinical Cell Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAIJIN LIFE SCI Shares Surge Over 60% Following Strategic Collaboration in Clinical Cell Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-22 15:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>BAIJIN LIFE SCI</b> (<b>01466</b>) have surged more than 60%. At the time of writing, the stock is up 50%, trading at HK$0.93 with a turnover of HK$12.29 million.<br><br>The significant movement follows a recent company announcement. The firm's indirectly wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with Fuyao Yuanqi Biotechnology Co., Ltd. (Fuyao Yuanqi). This agreement pertains to strategic collaboration within the clinical cell therapy field.<br><br>Fuyao Yuanqi's core technology originates from the commercialization of scientific research achievements from leading Chinese higher education and research institutions. The company has established specialized technology transfer cooperation arrangements and has secured exclusive licensing for related patents. Fuyao Yuanqi also possesses experience in filing for clinical cell drug research.<br><br>Previously, Beijing Baijin, the indirectly wholly-owned subsidiary of <b>BAIJIN LIFE SCI</b>, signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. (Youhuan Bio). Under this agreement, Beijing Baijin will invest in Youhuan Bio by subscribing to its equity. The aim is to establish a globally leading circular RNA (circRNA) technology research and development platform and, by leveraging this platform, to deepen technological innovation in the cell therapy sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1151123163","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151123163","pubTimestamp":1782114744,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of BAIJIN LIFE SCI (01466) have surged more than 60%. At the time of writing, the stock is up 50%, trading at HK$0.93 with a turnover of HK$12.29 million.The significant movement follows a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1227":"服装、服饰与奢侈品","01466":"佰金生命科学"},"translate_title":"临床细胞治疗战略合作后，百金生命SCI股价飙升逾60%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"01466":1},"content_text":"Shares of BAIJIN LIFE SCI (01466) have surged more than 60%. At the time of writing, the stock is up 50%, trading at HK$0.93 with a turnover of HK$12.29 million.The significant movement follows a recent company announcement. The firm's indirectly wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with Fuyao Yuanqi Biotechnology Co., Ltd. (Fuyao Yuanqi). This agreement pertains to strategic collaboration within the clinical cell therapy field.Fuyao Yuanqi's core technology originates from the commercialization of scientific research achievements from leading Chinese higher education and research institutions. The company has established specialized technology transfer cooperation arrangements and has secured exclusive licensing for related patents. Fuyao Yuanqi also possesses experience in filing for clinical cell drug research.Previously, Beijing Baijin, the indirectly wholly-owned subsidiary of BAIJIN LIFE SCI, signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. (Youhuan Bio). Under this agreement, Beijing Baijin will invest in Youhuan Bio by subscribing to its equity. The aim is to establish a globally leading circular RNA (circRNA) technology research and development platform and, by leveraging this platform, to deepen technological innovation in the cell therapy sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}